Currently authorised for use in those aged over 12
European Health Regulators are examining an application for approval for the use of the Pfizer-BioNTech Covid-19 vaccine, in children aged 5 to 11.
The inolculation is currently authorised for use in those aged 12 and over.
The European Medicines Agency says it will review the data on the vaccine, including results from an ongoing clinical study, in order to decide whether to recommend extending its use.
The EMA says the evaluation is expected to take a couple of months.
The vaccine was first authorised for use in adults, in December 2020.
EMA starts evaluating an application to extend the use of BioNTech/Pfizer’s COVID-19 vaccine, #Comirnaty, to children aged 5 to 11.
— EU Medicines Agency (@EMA_News) October 18, 2021
Read the full press release:
👉https://t.co/j07hskkjRO#COVID19vaccines pic.twitter.com/EENKB10NcV